Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Pinkawa, Michael ^a   Piroth, Marc D ^a   Holy, Richard ^a   Djukic, Victoria ^a   Klotz, Jens ^a   Pfister, David ^a   Heidenreich, Axel ^a   Eble, Michael J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Brachytherapy; Hormone therapy; Ir 192; Prostate cancer; Prostate specific antigen; Radiotherapy

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; IRIDIUM 192;

ADULT; AGE; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROSTATE CANCER; RADIATION DOSE; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HORMONES; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84872722047     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-209     Document Type: Article

References (24)

1. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F. EAU guidelines on prostate cancer, part 1: screening, diagnosis and treatment of clinically localised disease. Eur Urol 2011, 59:61-71. 10.1016/j.eururo.2010.10.039, 21056534.
2. Pinkawa M. External beam radiotherapy for prostate cancer. Panminerva Med 2010, 52:195-207.
3. Pinkawa M, Piroth DM, Holy R, Fischedick K, Schaar S, Borchers H, Heidenreich A, Eble MJ. Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer. Radiother Oncol 2010, 96:25-29. 10.1016/j.radonc.2010.02.010, 20231039.
4. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy: results from the prostate cancer results study group. BJU Int 2012, 109(Suppl.1):22-29.
5. Gill S, Thomas J, Fox C, Kron T, Rolfo A, Leahy M, Chander S, Williams S, Tai KH, Duchesne GM, Foroudi F. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol 2011, 6:145. 10.1186/1748-717X-6-145, 3217047, 22035354.
6. Prada PJ, Mendez L, Fernández J, González H, Jiménez I, Arrojo E. Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer. Radiat Oncol 2012, 7:31. 10.1186/1748-717X-7-31, 3310720, 22397528.
7. Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, Caffaro M, Winz OH, Krohn T, Mottaghy FM, Eble MJ. Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol 2012, 7:14. 10.1186/1748-717X-7-14, 3299580, 22289620.
8. Bolla M, van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073. 10.1016/S1470-2045(10)70223-0, 20933466.
9. Bolla M, de Reijke TM, van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527. 10.1056/NEJMoa0810095, 19516032.
10. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21:3972-3978. 10.1200/JCO.2003.11.023, 14581419.
11. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290. 10.1016/j.ijrobp.2004.08.047, 15817329.
12. Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide early prostate cancer programme at a median follow-up of 9.7 years. BJU Int 2010, 105:1074-1081. 10.1111/j.1464-410X.2010.09319.x, 22129214.
13. Kucway R, Vicini F, Huang R, Stromberg J, Gonzalez J, Martinez A. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002, 167:2443-2447. 10.1016/S0022-5347(05)65001-X, 11992054.
14. Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G. Final report of a multicenter Canadian phase III randomized trial of 3 vs. 8 months neoadjuvant androgen deprivation before conventional dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:327-333. 10.1016/j.ijrobp.2008.04.075, 18707821.
15. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, Lukka HR, Levine M. Randomized trial comparing Iridium implant plus external-beam radiotherapy with external-beam radiotherapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23:1192-1199. 10.1200/JCO.2005.06.154, 15718316.
16. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012, 103:217-222. 10.1016/j.radonc.2012.01.007, 22341794.
17. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure follwing radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974. 10.1016/j.ijrobp.2006.04.029, 16798415.
18. Souhami L, Bae K, Pilepich M, Sandler H. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer: a secondary analysis of RTOG 85-31. J Clin Oncol 2009, 27:2137-2143. 10.1200/JCO.2008.17.4052, 2674000, 19307511.
19. Viani GA, Stefano EJ, Alfonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment. Int J Radiat Oncol Biol Phys 2009, 74:1405-1418. 10.1016/j.ijrobp.2008.10.091, 19616743.
20. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011, 12:451-459. 10.1016/S1470-2045(11)70063-8, 21440505.
21. Alexander AA, Crook J, Jones S, Malone S, Bowen J, Truong P, Pai H, Ludgate C. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys 2010, 76:23-30. 10.1016/j.ijrobp.2009.01.030, 19395187.
22. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial (INT-0162). J Clin Oncol 2006, 24:3984-3990. 10.1200/JCO.2006.06.4246, 16921051.
23. Oefelein MG, Agarwal PK, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 2004, 171:1525-1528. 10.1097/01.ju.0000118294.88852.cd, 15017212.
24. Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer. Eur Urol 2006, 49:666-674. 10.1016/j.eururo.2005.11.032, 16423446.